Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.42 |
| ▸ | KDR | P35968 | 8/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114775 | 0.86 | KDR (0.58) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL29746649 | 0.86 | KDR (0.58) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL29523346 | 0.82 | KDR (0.59) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL15114776 | 0.78 | KDR (0.68) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL29746661 | 0.78 | KDR (0.68) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL14714846 | 0.77 | KDR (0.62) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL548163 | 0.76 | RAF1 (0.64) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL5502095 | 0.74 | KDR (0.61) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL548196 | 0.72 | RAF1 (0.55) | BRAFKDRMAPK14RIPK2ABCB11 | |
| SCHEMBL4255951 | 0.69 | KDR (0.67) | BRAFKDRMAPK14RIPK2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | PDCD1, CD274, PDCD1LG2 | BRAF 9/4885KDR 1071/4885MAPK14 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.